{
    "Trade/Device Name(s)": [
        "Hipro Glycosylated Hemoglobin (HbA1c) Test System",
        "Hipro Glycosylated hemoglobin (HbA1c) test kit",
        "HP-AFS/1 automatic immunoassay analyzer"
    ],
    "Submitter Information": "Shijiazhuang Hipro Biotechnology Co., Ltd.",
    "510(k) Number": "K220999",
    "Predicate Device Reference 510(k) Number(s)": [
        "K151321"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ",
        "LCP"
    ],
    "Summary Letter Date": "October 13, 2023",
    "Summary Letter Received Date": "October 13, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1373"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Venous whole blood",
        "Human Whole blood"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "HP-AFS/1 automatic immunoassay analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Nephelometry Immunoassay Method"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Test Kit",
        "Analyzer",
        "Reagent",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Hipro Glycosylated Hemoglobin (HbA1c) Test System using nephelometry immunoassay for quantitative determination of % HbA1c in venous whole blood",
    "Indications for Use Summary": "Aid in diagnosis of diabetes mellitus, identification of risk for developing diabetes, and monitoring of long-term blood glucose control in individuals with diabetes mellitus via quantitative determination of % hemoglobin A1c in venous whole blood",
    "fda_folder": "Clinical Chemistry"
}